锁仓再加码！Mirxes创始人+基石集体陪跑，解码背后价值与增长底气

Core Viewpoint - Mirxes has announced a new voluntary lock-up plan initiated by its co-founders and cornerstone investors, signaling a strong commitment to the company's long-term growth and value, rather than merely stabilizing the stock price in the short term [1][3][4] Group 1: Lock-Up Plan Significance - The recent lock-up announcement is viewed as a proactive endorsement of the company's value and market potential by its co-founders and cornerstone investors, rather than a passive measure to stabilize the stock [2][3] - The commitment includes a promise from co-founders not to sell any shares and a commitment from cornerstone investors to hold at least 80% of their shares for an additional 12 months [3][4] Group 2: Financial Perspective - Early investors lack immediate incentives to sell their shares due to the cost structure and potential returns, creating a significant barrier between the concepts of "unlocking" and "selling" [5][6] - C-round investors' holding cost is approximately 22.21 HKD per share, while D-round investors' cost is around 22.92 HKD per share, indicating limited profit margins at the current stock price of 24.00 HKD [6][7][8] Group 3: Long-Term Capital Support - The investor structure of Mirxes, which includes long-term capital from various institutional investors, provides a solid foundation for future growth [9][10] - Notable long-term investors include state-owned funds and specialized healthcare investment firms, which not only provide financial backing but also strategic support for commercialization and international expansion [10][11] Group 4: Conclusion - The lock-up plan, combined with the financial rationale of early investors and the backing of long-term capital, reinforces the confidence in Mirxes' future growth potential [12][13] - The company's core product, "Mi Xiao Wei," has received regulatory approval and is expanding into multiple cancer screening markets, further solidifying its position in the industry [13][14]